ABBV

SEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,286

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002945 · form4-02212023_110202.xml · derivative · entry 10

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,957

Underlying: Common Stock · 22,957 shares

Expires 2033-02-15

F9 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,653 on February 16, 2024, 7,652 on February 16, 2025, and 7,652 on February 16, 2026.

SEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,208

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,828

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,268

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002945 · form4-02212023_110202.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,039

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 11

Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,205

Underlying: Common Stock · 16,205 shares

Expires 2033-02-15

F9 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,402 on February 16, 2024, 5,402 on February 16, 2025, and 5,401 on February 16, 2026.

SEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 2

Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,283

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,209

F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-000086 · form4-01032023_100105.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,256

Underlying: Common Stock · 239 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F3 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-000087 · form4-01032023_100102.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,723

Underlying: Common Stock · 46 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F3 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-012547 · form4-12142022_101246.xml · derivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,370 shares

Expires 2026-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section16 under Rule 16b-3.

SEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,837

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.08 to $164.18, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,912

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.02 to $164.00, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-22-012547 · form4-12142022_101246.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-010242 · form4-10042022_021018.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,598

Underlying: Common Stock · 55 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-010247 · form4-10042022_021024.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,806

Underlying: Common Stock · 288 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-007379 · form4-07052022_020714.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,296

Underlying: Common Stock · 237 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-007380 · form4-07052022_020740.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,458

Underlying: Common Stock · 47 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 8

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,478

Underlying: Common Stock · 21,739 shares

Expires 2031-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 7

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,188

Underlying: Common Stock · 11,742 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003137 · edgar.xml · derivative · entry 6

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,320 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 5

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,103

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 4

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,708

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 3

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 2

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003137 · edgar.xml · nonDerivative · entry 1

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 14

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,930

Underlying: Common Stock · 64,636 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 13

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,364 shares

Expires 2029-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 10

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,103

F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 9

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,203

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 8

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,482

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 7

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 6

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003076 · edgar.xml · derivative · entry 5

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,960 shares

Expires 2026-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003076 · edgar.xml · nonDerivative · entry 2

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,623

SEC source: 0001179110-22-003076 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 12

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,364

Underlying: Common Stock · 29,121 shares

Expires 2029-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003077 · edgar.xml · derivative · entry 11

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,879 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 5

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,103

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 4

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,503

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 3

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,830

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 2

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003077 · edgar.xml · nonDerivative · entry 1

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003108 · edgar.xml · derivative · entry 5

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,960 shares

Expires 2026-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-003108 · edgar.xml · nonDerivative · entry 2

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,623

SEC source: 0001179110-22-003108 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-22-003023 · edgar.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,663

SEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 21

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,879

Underlying: Common Stock · 29,221 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 20

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,779 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.